Literature DB >> 2498253

Synthesis of an inhibitor of human immunodeficiency virus infection.

K Hatanaka1, T Yoshida, T Uryu, O Yoshida, H Nakashima, N Yamamoto, T Mimura, Y Kaneko.   

Abstract

Anti-HIV effects of lentinan sulfate were investigated by using an HTLV-I-carrying cell line, MT-4, in vitro. Lentinan, a fungal branched (1----3)-beta-D-glucan, was sulfated to various degrees by means of two kinds of procedures using piperidine N-sulfonic acid in dimethyl sulfoxide or chlorosulfonic acid in pyridine. Lentinan sulfate with a sulfur content of more than 13.9% effectively prevented HIV-induced cytopathic effects (CPE) at concentrations of more than 3.3 micrograms/ml. However, low-substituted lentinan sulfate did not prevent HIV-induced CPE at any concentration tested. When the countercation was 50% Na+ and 50% pyridinium ion, the inhibitory capacity was low. Anticoagulant activity of the lentinan sulfate was also assessed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498253      PMCID: PMC5917693          DOI: 10.1111/j.1349-7006.1989.tb02272.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  15 in total

1.  Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae.

Authors:  H Nakashima; Y Kido; N Kobayashi; Y Motoki; M Neushul; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

Authors:  M Ito; M Baba; A Sato; R Pauwels; E De Clercq; S Shigeta
Journal:  Antiviral Res       Date:  1987-07       Impact factor: 5.970

3.  Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro.

Authors:  H Nakashima; O Yoshida; T S Tochikura; T Yoshida; T Mimura; Y Kido; Y Motoki; Y Kaneko; T Uryu; N Yamamoto
Journal:  Jpn J Cancer Res       Date:  1987-11

4.  Sulfation of dextran with piperidine-N-sulfonic acid.

Authors:  K Nagasawa; H Harada; S Hayashi; T Misawa
Journal:  Carbohydr Res       Date:  1972-03       Impact factor: 2.104

5.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

6.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

Review 8.  Human T-lymphotropic retroviruses.

Authors:  F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

9.  Sulfation of the immunomodulating polysaccharide lentinan: a novel strategy for antivirals to human immunodeficiency virus (HIV).

Authors:  O Yoshida; H Nakashima; T Yoshida; Y Kaneko; I Yamamoto; K Matsuzaki; T Uryu; N Yamamoto
Journal:  Biochem Pharmacol       Date:  1988-08-01       Impact factor: 5.858

10.  Synthesis of new heparinoids with high anticoagulant activity.

Authors:  K Hatanaka; T Yoshida; S Miyahara; T Sato; F Ono; T Uryu; H Kuzuhara
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

View more
  1 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.